(NEW YORK) — The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain.
The drug, called Journavx (suzetrigine) and manufactured by biotech company Vertex Pharmaceuticals, is a non-opioid painkiller, which doesn’t have addictive properties, unlike opioids often used for this type of pain.
This is the first class of non-opioid pain medication approved to treat moderate to severe acute pain approved by the FDA in more than 20 years.
“Today’s approval is an important public health milestone in acute pain management,” said Dr. Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, in a press release. “A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment option.”
In two clinical trials, tested on adults between ages 18 and 80, Journavx was found to reduce moderate to severe acute pain for adults from baseline by about 50% in 48 hours.
The average time to meaningful pain relief ranged from two to four hours, compared to eight hours in the placebo group.
Journavx works by inhibiting the NaV1.8 pain signal in the peripheral nervous system. This channel is not expressed in the brain or anywhere else in the central nervous system, therefore the drug does not have addictive properties like opioids, according to Vertex.
Journavx was found to be as similarly effective as hydrocodone, an opioid pain medication, for reducing acute pain, with the added benefit of being a non-opioid and non-addictive drug.
In another clinical trial, the drug was tested in patients with a broader range of surgical and non-surgical acute pain conditions and was found to be safe and effective.
More than 80% of patients in this clinical trial rated Journavx as a good, very good or excellent pain medication when investigating multiple acute pain types.
The new drug “offers a safer option for managing moderate-to-severe acute pain, reducing reliance on opioids,” Dr. Jianguo Cheng, a professor of anesthesiology and medical director of the Cleveland Clinic Consortium for Pain at Cleveland Clinic, who was not involved in the clinical trials, told ABC News. “It offers rapid relief and can be integrated into postoperative pain protocols or acute pain scenarios where immediate relief is critical.”
“By managing acute pain effectively, [Journavx] may help prevent the transition to chronic pain, reducing the need for long-term pain management strategies,” he added.
(WASHINGTON) — When the White House budget office released a memo this week that instructed all federal agencies to cease spending on any financial assistance programs pending internal review, the fate of the nation’s largest public health insurance program was propelled into question.
Medicaid is a joint federal and state program that provides health care coverage to low-income individuals and families. There were over 79 million Americans enrolled in the program as of October 2024.
The online Medicaid reimbursement portal accessible by every state was reportedly down following Tuesday’s freeze announcement, despite the White House Office of Management and Budget saying in an updated memo that the program would not be affected.
On Wednesday, after being temporarily blocked by a federal judge and already facing a legal challenge from 22 state attorneys general, the freeze was rescinded.
While federal administrators and private individuals alike scramble to understand which programs could be affected by President Donald Trump’s sweeping executive orders, experts say Medicaid’s role in America cannot overstated.
“It’s really the backbone of many aspects of our health care system,” Joan Alker, executive director of Georgetown University’s Center for Children and Families, told ABC News.
From birth to elder care, Medicaid covers newborns, children, low-income individuals and families, people with disabilities and substance abuse issues, and nursing home residents, among others, according to Alker.
“I think we all need to really pay attention to what’s going on here, both in the administration but, more importantly, in Congress, where they are contemplating these very large cuts,” Alker said.
What is Medicaid?
Medicaid, which turns 60 this year, was established in 1965 as amendments to Social Security by President Lyndon B. Johnson. The program was meant to provide health insurance to individuals and families who could not afford or were not provided private insurance through employment.
Now, it’s a nearly $900 billion program funded by both the federal government and individual states, with each state administering its own eligibility, benefits and payment rates based on federal guidelines, according to the program’s website.
The federal government reimburses states for a portion of Medicaid costs through the Federal Medical Assistance Percentage program, which covers hospitals, doctors, clinics, pharmacies and nursing homes with little to no copayments by the beneficiaries, according to Medicaid.
“Medicaid serves a key role in the health insurance market, and for many people, there is no alternative,” Eric Seiber, Ph.D., a professor in the College of Public Health and director of the Center for Health Outcomes and Policy Evaluation Studies at Ohio State University, told ABC News.
“This affects Medicaid beneficiaries, but also Medicaid providers. What is often overlooked is one person’s healthcare expense is another person’s healthcare income,” Seiber added.
How many Americans are on Medicaid?
As of October 2024, the program reported that 79.4 million people were enrolled in Medicaid across the U.S. That includes 41.7 million adults enrolled in Medicaid and 37.6 million Medicaid child and Children’s Health Insurance Program enrollees.
Medicaid enrollment is on the rise, with the program seeing a 20% increase in applications since October 2023 and a 66% increase since October 2022, according to the program.
Who is eligible for Medicaid?
Eligibility for Medicaid coverage is based on income, family size, disability status and age, and can vary from state to state.
The expansion of Medicaid through the Affordable Care Act made adults with incomes of up to 138% of the federal poverty level, or about $20,783 for an individual, eligible in 2024, according to the program.
Not everyone to enrolls in Medicaid remains on it indefinitely, according to Seiber.
“Medicaid often serves as a trampoline, not a safety net. People land on Medicaid and often bounce right back off,” Seiber told ABC News of Medicaid’s role in the American health care system.
“I would say that Medicaid protects people’s health, but also their future,” Seiber added.
Medicaid during Trump’s first administration
Trump’s first administration saw threats to Medicaid and the Affordable Care Act that were ultimately rejected, perhaps most dramatically in 2017 when Sen. John McCain, who died of brain cancer the following year, returned to Washington, D.C., to vote against the so-called “skinny repeal” of the ACA and hundreds of billions in cuts to Medicaid.
Trump was attempting to replace the ACA with the American Health Care Act, which would have repealed the individual mandate and the employer mandate, amended Medicaid eligibility and weakened protections for patients with pre-existing conditions.
In December 2017, a Republican tax reform law was passed that eliminated individual mandates, which Gallup later said may have reduced participation in the insurance marketplace.
At the end of 2019, 13.7% of adults were without health insurance, the highest level seen since early 2014, according to Gallup data.
Fast-forward to the 2024 election cycle: Trump made little mention of Medicaid amid various campaign trail comments about possible changes to Medicare and Social Security.
In March, Trump wrote in a post on Truth Social that he was “not running to terminate” the ACA but said he wanted to make it “better” and “less expensive.”
During the September presidential debate, he said he had “concepts of a plan” and said it would be “better health care than Obamacare,” but offered few details.
“Medicaid will be turning 60 this year, so we are very concerned that that proposal may arise again,” Alker said of possible cuts to federal Medicaid funding.
“So our future is really at stake here, and I think with an aging population, with a growing need for long-term care, there’s no way that states can manage this,” she added.
(NEW YORK) — Kansas is facing the largest recorded tuberculosis outbreak in U.S. history, according to local health officials.
As of Jan. 24, there have been 67 confirmed cases of active TB including 60 in Wyandotte County and seven in Johnson County, according to the Kanas Department of Health and Environment.
Additionally, there are 79 confirmed latent TB cases, including 77 in Wyandotte County and two in Johnson County. Wyandotte County contains part of Kansas City and Johnson County is just southwest of Kansas City.
Cases linked to the outbreak were first reported in January 2024, according to KDHE. So far, there have been two deaths related to the outbreak, both of which occurred last year.
“The current Kansas City, Kan. Metro tuberculosis (TB) outbreak is the largest documented outbreak in U.S. history, presently (since the 1950s, when the Centers for Disease Control and Prevention (CDC) started monitoring and reporting TB cases),” KDHE said in a statement. “This outbreak is still ongoing, which means that there could be more cases.”
Health officials say the risk to people living in surrounding counties and to the general public is “very low,” and that the department is following guidance from the Centers for Disease Control and Prevention.
TB is a disease caused by a type of bacteria called Mycobacterium tuberculosis, according to the CDC. It is one of the world’s leading infectious disease killers, the federal health agency says.
TB is spread in the air from one person to another. When a person with TB coughs, speaks or sings, germs are expelled into the air — where they can linger for several hours — before another person breathes in the air and becomes infected.
Signs and symptoms include a cough that lasts for three weeks or longer, coughing up blood or phlegm, chest pain, weakness, fatigue, weight loss, loss of appetite, fever, chills and night sweats, according to the CDC.
Some people become infected with TB germs that live in the body for years without causing illness. This is known as inactive TB or latent TB.
People with inactive TB do not feel ill, do not have symptoms and cannot spread germs to other people, the CDC says. However, without receiving treatment, people with inactive TB can develop active TB.
Last year, the U.S. saw more than 8,700 cases of TB, according to CDC data. Although TB cases have been steadily declining since the mid 1990s, rates increased in 2021, 2022 and 2023, with 2023 matching pre-pandemic levels.
There are several treatment regimens for TB disease that may last anywhere from four months to nine months depending on the course of treatment. Health care providers may consider specific regimens for patients with co-existing medical conditions such as diabetes or HIV.
A vaccine, known as Bacille Calmette-Guérin (BCG), is commonly given to children in countries where TB is common, although it is generally not recommended in the U.S. due to the low risk of infection with the bacteria, variable vaccine effectiveness among adults, and the vaccine’s potential interference with TB tests, the CDC notes. The BCG vaccine often leaves a scar where the recipient was given the shot.
(NEW YORK) — Heart disease remains the leading cause of death in the United States, according to a new report.
The American Heart Association (AHA) report, published Monday in the journal Circulation, found that 941,652 Americans died from cardiovascular disease in 2022, the most recent year for which data is available. That’s an increase of more than 10,000 from the just over 931,500 reported to have died from cardiovascular disease in 2021.
It also means that a person in the U.S. dies of cardiovascular disease every 34 seconds, or nearly 2,500 people every day, according to the AHA report.
“The stats are pretty sobering from this report,” Dr. Tara Narula, ABC News chief medical correspondent and a board-certified cardiologist, said on ABC’s “Good Morning America” on Monday. “In fact, cardiovascular disease kills more Americans than all forms of cancer and accidents combined.”
Cancer and accidental deaths continue to remain the second and third leading causes of death, respectively, according to the latest data from the Centers for Disease Control and Prevention (CDC).
The AHA report also found racial and ethnicity disparities, with Black Americans having the highest prevalence of cardiovascular disease. Between 2017 and 2020, 59% of non-Hispanic Black females and 58.9% of non-Hispanic Black males had some form of the disease, according to the report.
In addition, the report showed several heart disease risk factors continue to rise, with nearly 47% of American adults having high blood pressure and more than half, 57%, diagnosed with type 2 diabetes or prediabetes.
Additionally, 72% of U.S. adults have an unhealthy weight, with nearly 42% of adults having obesity, which also is a risk factor for developing cardiovascular disease, according to the AHA report.
In an accompanying editorial, Dr. Dhruv Kazi, associate director of the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center In Boston, said risk factors for cardiovascular disease are expected to rise over the next several years.
“Although we have made a lot of progress against cardiovascular disease in the past few decades, there is a lot more work that remains to be done,” Kazi wrote. “If recent trends continue, hypertension and obesity will each affect more than 180million U.S. adults by 2050, whereas the prevalence of diabetes will climb to more than 80 million.”
Overall, cardiovascular-related deaths have begun plateauing after ticking upward during the COVID-19 pandemic, according to the AHA. The report found death rates dropped during the survey period for all 10 leading causes of death except kidney disease, which increased by 1.5%.
The good news is that 80% of cardiovascular disease is preventable, according to Narula. Ways to lower the risk include eating a heart-healthy diet, getting regular exercise, quitting smoking, managing stress, and getting adequate sleep every night.
Beauty influencer Ashley Stobart discusses how she got a facelift after removing fillers from her face/ABC News
(NEW YORK) — Celebrities are increasingly opening up about reversing cosmetic procedures and swearing off dermal fillers, but some have discovered it can come with unexpected consequences.
“Friends” actress Courteney Cox spoke about removing her fillers on the “Gloss Angeles” podcast in 2023.
“I was just doing too many fillers and then having to have them removed which, thank God they are removable, but I think I’ve messed — I messed up a lot and now, luckily, I can, you know, I was able to reverse most of that,” the 60-year-old said.
“IMPACT x Nightline: Facelift: After Fillers?” streams on Hulu beginning Jan. 23.
Reality TV star Lala Kent known for “Vanderpump Rules” discussed her change of heart with BravoTV.com.
“I wanna stop with the lips, I wanna stop with the fillers, you know, it’s just enough is enough,” the 34-year-old said. “I’m starting to look at the comments and compare photos, I’m not about it anymore.”
In 2023, model Blac Chyna told “Impact x Nightline” about how losing weight prompted her to have cosmetic work reversed at age 34.
“As I started to slim down, my features started to really come out, like my cheekbones and everything. So with all the filler, that started to really protrude out now that my face has become slimmer,” she said. “It served its purpose, like I’m just, I’m cutting ties with it so I can move on to the next chapter in my life.”
UK beauty influencer and podcaster Ashley Stobart shares her reflections on cosmetic procedures with followers on her podcast “Nip, Tuck, Not Giving A…” She got nonsurgical injections of lip filler when she was 18 — the earliest age it’s legal to do so in her country.
“It was just that quick fix I needed for maybe loss of volume, wanting bigger lips, bigger cheeks, the jaw filler, the chin filler, the nose filler,” she told ABC News. “I was having all the filler.”
Hyaluronic acid, which is commonly used for fillers, is a gel-like substance that’s injected into spaces to give an appearance of plumpness, according to ABC News medical correspondent Dr. Darien Sutton.
He noted that the internet is flooded with ads for med spas offering seemingly cheap deals on fillers and Botox.
“When you scroll online, you see advertisements for things like fillers — that should be a red flag,” Sutton said. “When you see people looking for customers, aka patients, trying to do procedures that they may not be fully skilled in doing, selling it at a discount, you know, these should be red flags.”
These injectables are sometimes described as dissolving over time, but Sutton said this isn’t always the case.
“We’re learning more and more that many of these substances are persistent in people’s bodies for longer than they may think,” he said. “And that exposes people to risks that we are only beginning to understand.”
When Stobart got pregnant, it meant she took a break from topping up her filler. Then she realized it hadn’t worn off.
“There were just multiple layers of treatments that I had accumulated over the years,” she said. “I’m looking bigger and puffier than ever.”
She decided to get her fillers reversed, but dissolving more than a decade’s worth of substances she had in her face left her with sagging skin. So she opted to get a face-lift at age 34.
She’s not alone. The American Society of Plastic Surgeons said that while the overwhelming majority of facelifts are still among people over 50, their members have observed an increase among people in their 40s and younger.
Even though Stobart had some of her fillers removed already, she said the face-lift surgery was grueling.
“They found a lot of hyaluronic acid, or remnants of some injectable at some point that I had had. They were pushing it out for hours,” she told ABC News. “I was in surgery for 9.5 hours in total. That wasn’t anticipated because when he opened everything up, it turned out there was still a lot left in there.”
Dr. Darien Sutton warned that the face is among the most complicated areas in the body due to the composition of blood vessels, nerves. and muscles, so the surgery requires expertise.
“The risk of complication is so high, and the risk of disfigurement is so high, that you have to make sure you’re doing it with someone who knows exactly what they’re doing,” he said.
Some people in their 20s and 30s are also sharing their surgical lift stories on social media. Ryan Joers is 26 years old, and started his cosmetic journey almost a decade ago with fillers.
“I had always seen on social media, other influencers,” he told ABC News. “Kylie Jenner, at that time was, I think, 16 years old, getting her lips done, and just seeing that kind of noise everywhere, seeing the influencers apply products to their lips that were beautiful and full was a big motivator.”
In the years that followed, Joers enjoyed being able to address perceived imperfections with filler. However, that changed when he was around 22.
“That was when I would smile — I didn’t see anything other than my lips,” he said. “I would see photos and videos of myself and just see lips.”
He acknowledged that he didn’t fully understand how fillers work when he first started getting them.
“Our knowledge on fillers was not what it was today, it was ‘fillers aren’t permanent.’ So you need more, you need more, you need more,” he said. “So I never really got the opportunity at first to understand different types of filler, how they interact differently in the body.”
After that, Joers began to undo what he had spent thousands of dollars and years of his life doing. He had some of his fillers dissolved and got a rhinoplasty, which is a plastic surgery that reshapes the nose. Then, at 25, he got a brow and eye lift.
“It was an interesting landscape, being, you know, a younger man — it comes with a lot of judgment from plastic surgeons,” he said. “You have to admit to someone not only that you made mistakes, but that you’re not happy with the way you look. And that’s a very vulnerable thing with anyone, whether it’s a friend or a doctor.”
Joers believes surgical lifts were his best option due to the limitations of the nonsurgical options available at med spas.
“I’m happier now with the way my face looks, given that surgery was an intervention or an option of altering my chin, altering my nose, altering my face in a way that naturally would have not been possible or achievable through a med spa procedure,” he said.
He hasn’t been afraid to be open and vulnerable about his journey, posting about his recovery and before-and-after shots on TikTok. His videos have been viewed hundreds of thousands of times, and he hopes telling his story will help those who are just starting their cosmetic journeys.
“I’m grateful for my experience, even the bad of it, because that’s how I got here,” he said. “Through that, I was able to learn and make better decisions when it came to permanent solutions.”
Having followed a similar path, Ashley Stobart told ABC News she hopes others learn from her story.
“I would just say, don’t rush into anything unless you’re 100% sure and you understand all of the pros and cons,” she said.
Purdue Pharma headquarters; Victor J. Blue/Bloomberg via Getty Images
(NEW YORK) — The company and once-prominent family behind the drug OxyContin agreed Thursday to increase their financial contribution to resolve mass opioid litigation.
The Sacklers and Purdue Pharma boosted their settlement contribution to $7.4 billion after the U.S. Supreme Court overturned a prior settlement in June 2024. If approved, the new plan would end the costliest corporate bankruptcy resulting from the U.S. opioid crisis.
Purdue, under the leadership of the Sackler families, invented, manufactured and aggressively marketed opioid products for decades, according to the lawsuits. States and cities across the country said it fueled waves of addiction and overdose deaths.
The pharmaceutical company introduced OxyContin, a brand name of oxycodone, in the 1990s and filed for chapter 11 bankruptcy in 2019 after the company was sued thousands of times.
Under the settlement terms, the Sacklers’ control of Purdue Pharma ends. The $7.4 billion will go directly to communities across the U.S. — including states, counties, cities and territories — over the next 15 years to support opioid addiction treatment, prevention, and recovery programs.
“Families throughout New York and across the nation are suffering from the immense pain and loss wrought by the opioid crisis,” said New York Attorney General Letitia James, whose office helped negotiate the settlement agreement.
“The Sackler family relentlessly pursued profit at the expense of vulnerable patients, and played a critical role in starting and fueling in the opioid epidemic,” she continued. “While no amount of money will ever fully repair the damage they caused, this massive influx of funds will bring resources to communities in need so that we can heal.”
Purdue Pharma planned to exit bankruptcy last year under terms that gave the Sacklers a full release from all civil opioid claims even though they themselves were not declaring bankruptcy. In return, the Sacklers agreed to pay $6 billion.
The Supreme Court rejected the attempt by the Sacklers to use Purdue Pharma’s bankruptcy to shield themselves from liability.
Under the new terms, a significant amount of the settlement funds will be distributed in the first three years, with the Sacklers paying $1.5 billion and Purdue paying nearly $900 million in the first payment, followed by $500 million after one year, an additional $500 million after two years, and $400 million after three years.
A board of trustees selected by participating states in consultation with the other creditors will determine the future of the company. Purdue will continue to be overseen by a monitor and will be prevented from lobbying or marketing opioids.
“This story is about a family of cruel billionaires who believed they were above the law, pursued by states who never backed down,” Connecticut Attorney General William Tong said Thursday. “Today, we are forcing Purdue Pharma and the Sackler family to pay $7.4 billion for their role in igniting one of the most devastating public health crises in American history.”
Purdue Pharma said in a statement to ABC News, “We are extremely pleased that a new agreement has been reached that will deliver billions of dollars to compensate victims, abate the opioid crisis, and deliver treatment and overdose rescue medicines that will save lives. We have worked intensely with our creditors for months in mediation, and we are now focused on finalizing the details of a new Plan of Reorganization, which we look forward to presenting to the bankruptcy court.”
(NEW YORK) — Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, alongside other influenza vaccines, health officials announced Friday.
The U.S. Department of Health and Human Services (HHS) said in a press release that the funding will allow the pharmaceutical company to accelerate the development of an H5N1 mRNA influenza vaccine “that is well matched to strains currently circulating in cows and birds and expands the clinical data supporting the use of mRNA vaccines that may be needed if other influenza strains emerge with pandemic potential.”
Moderna said the funding will support the expansion of clinical studies “for up to five additional subtypes of pandemic influenza.”
The U.S. government previously awarded the vaccine manufacturer $176 million in July 2024 to help expedite the development of an mRNA vaccine that could be used for bird flu.
mRNA technology is the same type that was used in the development of some COVID-19 vaccines. While some vaccines use a weakened or inactive virus to stimulate an immune response, mRNA vaccines teach the body how to make proteins that can trigger an immune response and fight off an infection.
Researchers can often design mRNA vaccines more quickly than they can produce the live or weakened pathogens needed for a live-attenuated or inactivated vaccine.
The federal government already has two bird flu vaccine candidates, which use traditional vaccine technology, available in the nation’s stockpile. Officials previously noted they’d have 10 million ready-to-use doses within the beginning of 2025. Vaccines were being stockpiled as a precaution.
“Avian flu variants have proven to be particularly unpredictable and dangerous to humans in the past. That is why this response has been a top priority for the Biden-Harris Administration and HHS,” HHS Secretary Xavier Becerra said in a statement on Friday. “Accelerating the development of new vaccines will allow us to stay ahead and ensure that Americans have the tools they need to stay safe.”
Bird flu cases in humans have been spreading across the country since April 2024 with 67 confirmed cases as of Friday, according to the Centers for Disease Control and Prevention (CDC).
The first death of a human bird flu patient was reported in Louisiana earlier this month. The patient was over the age of 65 and had underlying medical conditions, according to health officials.
Most human cases have occurred after coming into contact with infected cattle, infected poultry farms or other culling operations.
The CDC and other public health officials say there is currently no evidence of human-to-human transmission and the risk to the general public is low.
ABC News’ Mary Kekatos contributed to this report.
(SAN FRANCISCO) — A child in San Francisco was recently confirmed to be the third human case of bird flu in the United States in which it’s unclear how the person got infected.
Most human cases have occurred after coming into contact with infected cattle, infected poultry farms or other culling operations.
The CDC and other public health officials say there is currently no evidence of human-to-human transmission and the risk to the general public is low.
Doctors tell ABC News they agree but, with few cases that have an unknown — or unclear — source of infection, there may be evidence of some cases slipping through the cracks.
“There are reassuring factors here, which is the child appears to have had mild disease recovered…and kind of mild symptoms,” Dr. Tony Moody, a professor of pediatrics and infectious diseases specialist at Duke University, told ABC News.
Moody added, “That’s reassuring on the one hand, but it’s also concerning, because we don’t know, does this represent the only case, or is it one of 10,000 cases that just haven’t made their way into the health care system?”
Health officials in San Francisco first reported the bird flu case in the child earlier this month before it was confirmed by the CDC.
The child experienced symptoms of fever and eye irritation, and has since fully recovered, officials said. Investigators said they’re looking into how the child was exposed to the virus.
A CDC spokesperson confirmed this is the second child infected with bird flu in the country, the first case being in late November in California, also with unknown exposure.
The agency noted this is the third time that an exposure source has not been identified for a bird flu case with most other cases directly linked to exposure by infected livestock.
Moody said it’s hard what to make of the case because, while the CDC has bumped up surveillance, there are still gaps.
“It’s not universal surveillance. We’re not able to capture all of the cases that we might like to catch,” Moody said. “And so, it’s kind of hard to know what to do with isolated data points like this, when you get a report of, yes, this is a confirmed case. But it’s also like, what is the actual denominator here? How many cases are there really out there? And it’s kind of hard to tell.”
“So, I’m not sure that the identification of this case tells us a whole lot, other than, yep, it’s circulating,” Moody added.
Dr. Meghan Davis, an associate professor of environmental health and engineering at Johns Hopkins Bloomberg School of Public Health, told ABC News that because many of the cases have been mild, people with similarly mild symptoms may not be getting tested for bird flu.
For example, someone with pink eye, also known as conjunctivitis, may not associate it with bird flu, even with recent exposure to cattle.
“I’m certain that we’re missing some cases, because not everybody is going to even go to a health care provider if they’re sick and get swabbed,” she said. “There may be people who have more mild symptoms, and it doesn’t graduate to the level of ‘I need to go to urgent care’ or ‘I need to go to the hospital.'”
Both Moody and Davis said more surveillance needs to be conducted to catch cases that fly under the radar. Davis points out that the CDC is already doing this, announcing Thursday it is calling for a shortened timeline for subtyping all tests that are positive with influenza A to identify non-seasonal influenza.
The CDC said it is reminding clinicians and laboratories to test for influenza in patients with suspected cases and to expedite subtyping to determine if they have bird flu rather than seasonal flu.
“The reason this is important is that what you do for someone who has seasonal flu may be a little bit different than what you do when you’re dealing with a virus that’s novel and you don’t know entirely what to expect clinically, and you don’t know entirely what to expect in terms of its potential to continue to spread,” Davis said.
Moody added that it’s reassuring the recent pediatric case in California did not occur within a cluster of cases, such as an entire family becoming infected.
He explained it would be much more jarring to have a cluster of cases with unconfirmed infection compared to an isolated case.
“When we see a report of a cluster of cases, that’s when my blood pressure is going to go up,” Moody said. “Given everything else we know, I think let’s keep our worry proportional for now.”
ABC News’ Youri Benadjaoud contributed to this report.
(NEW YORK) — Women are now being diagnosed with cancer more often than men in certain age groups, according to a new report from the American Cancer Society.
Among adults aged 50-64, cancer rates are slightly higher in women, and women under 50 are almost twice as likely as men in the same age group to receive a cancer diagnosis.
The report, released Thursday, found that while deaths continue to decrease, troubling racial disparities persist, with white Americans more likely to survive cancer than other groups.
Meanwhile, the report echoed data from recent years suggesting a worrying increase in cancer diagnosis among younger Americans, with colon cancer rates increasing among adults 65 and younger.
Broadly, the report suggested doctors are getting better at saving lives thanks to better treatments but reinforced worrying trends around rising diagnoses of some cancers, particularly among women. Changes in screening practices, lifestyle factors, obesity, environmental hazards and lower rates of smoking in men may be contributing to the trend, the report said.
Alcohol in particular was singled out as a possible lifestyle factor that may increase the risk of some cancers.
“For colorectal cancer, for example, it seems to be really excessive [alcohol intake] that is associated with increased risk of this cancer, whereas for breast cancer, there doesn’t seem to be any safe level of alcohol, but the elevated risk is small,” said Rebecca Seigel, senior scientific director of cancer surveillance research for the American Cancer Society.
As Seigel explained, higher rates of cancer in young people could also be part of a “generational impact” where people are diagnosed earlier in life and less frequently when they are older.
Lung cancer remains particularly deadly, with 2.5 times more deaths than colorectal and pancreatic cancer. Smoking continues to be the leading preventable cause of lung cancer, but other contributors, such as radon, air pollution and genetic mutations, may be driving cases.
“Overall, in this country, nonsmoking lung cancer, by itself, would be the eighth leading cause of cancer mortality, and worldwide, it would be the fifth leading,” said Dr. William Dahut, the American Cancer Society’s chief science officer.
Disparity rates in cancer outcomes remain striking as well, especially for minority populations.
Uterine corpus cancer, for example, has lower survival rates now than 40 years ago, with Black women at 63% survival compared to 84% for white women. Black men and women also face some of the highest death rates for prostate and breast cancers.
“I think the stubborn resistance in terms of outcomes among underrepresented minorities is a concern,” said Dr. Wayne A. I. Frederick, interim chief executive officer of the American Cancer Society.
“We have our VOICES program, which is an attempt to enroll as many African American women from across the country in a longitudinal study, something that hasn’t been done to try to answer some of these questions as to why that persistent burden is there,” he added.
The report does include some good news. While it predicts around 1,700 deaths from cancer per day in 2025, cancer death rates have fallen by 34% since their peak in 1991, preventing nearly 4.5 million deaths over the past three decades. This progress is largely attributed to declines in smoking, earlier detection for certain cancers, and advances in treatment, including breakthrough therapies like immunotherapy and targeted drugs.
Prevention has been a critical focus too, with initiatives like smoking cessation programs and HPV vaccination playing pivotal roles in reducing cancer risk. Public health efforts targeting obesity, alcohol use and expanding access to screenings have also helped tackle preventable cancers by improving early detection.
Cancer experts stress the importance of staying current with screening recommendations. For example, the American Cancer Society recommends most people start screening for colorectal cancer at age 45 or even sooner if you have a family history. For breast cancer, mammogram screening should start at age 40 for women with normal risk and earlier for women at high risk.
The report is a call for people to understand their family history better and take steps to reduce cancer risk, Dahut noted.
“Being proactive on your diet, on your exercise, avoiding tobacco, getting your vaccinations and monitoring alcohol are really all important ways to actually prevent cancer,” he said, adding that research efforts are also focused on finding new ways to detect cancer.
Miranda Guerriero, D.O., is a resident physician at University of Texas at Tyler and a member of the ABC News Medical Unit.
Canned cherries made with red dye #3/Photo credit: Linnea Bullion For The Washington Post via Getty Images
(WASHINGTON) — The U.S. Food and Drug Administration is moving to ban the use of Red No. 3 dye in food products.
The agency said Wednesday it is amending its color additive regulations to no longer allow the use of Red No. 3 in food, beverages and ingested drugs, in response to a 2022 petition from health groups and activists.
FD&C Red No. 3, also known as Red 3, is a synthetic food dye that gives foods and drinks a bright, cherry-red color. It is primarily used in foods such as candy, cakes and cupcakes, cookies, frozen desserts, frosting and icings, and some ingested drugs.
At least two studies have shown that high levels of the food dye were linked to cancer in rats. However, the link between the dye and cancer does not occur in humans, the FDA says.
While studies in other animals and humans did not show this link of cancer, an FDA regulation prohibits the agency to authorize color additive found to induce cancer in humans or animals, pushing the agency to revoke the food dye’s authorization.
Food manufacturers will have until 2027 to reformulate their products while drugmakers will have until 2028.
FDA Commissioner Robert Califf was asked at a Senate hearing in December why the dye had not been banned. He said the FDA hasn’t been given the resources to do the kind of post-market monitoring of substances done in Europe, where it has been largely banned since 1994. The FDA also banned the use of Red 3 in cosmetics in 1990.
“We have repeatedly asked for better funding for chemical safety … Please look at our request for funding for the people who do this work, remember that when we do ban something, it will go to court, and if we don’t have the scientific evidence … we will lose in court,” Califf said at the hearing.
Red 40, another synthetic food dye used to achieve a bright crimson color in condiments and candy, will remain available for use. Some studies have also shown Red 40 is a carcinogen in animals.
Red No. 3 was first approved by the FDA in 1969 and had been reviewed “multiple times” since then, according to the agency.
ABC News’ Kelly McCarthy contributed to this report.
